ELEV vs. FENC, KOD, ADVM, IPSC, GNFT, INMB, CGEN, OPT, IPHA, and CLLS
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Fennec Pharmaceuticals (FENC), Kodiak Sciences (KOD), Adverum Biotechnologies (ADVM), Century Therapeutics (IPSC), Genfit (GNFT), INmune Bio (INMB), Compugen (CGEN), Opthea (OPT), Innate Pharma (IPHA), and Cellectis (CLLS). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals (NASDAQ:FENC) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
Fennec Pharmaceuticals has higher revenue and earnings than Elevation Oncology. Elevation Oncology is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals received 168 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 69.44% of users gave Elevation Oncology an outperform vote while only 65.65% of users gave Fennec Pharmaceuticals an outperform vote.
55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 11.3% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 14.9% of Elevation Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fennec Pharmaceuticals presently has a consensus target price of $16.00, indicating a potential upside of 124.72%. Elevation Oncology has a consensus target price of $7.40, indicating a potential upside of 104.99%. Given Elevation Oncology's higher probable upside, analysts clearly believe Fennec Pharmaceuticals is more favorable than Elevation Oncology.
Fennec Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
In the previous week, Fennec Pharmaceuticals had 24 more articles in the media than Elevation Oncology. MarketBeat recorded 31 mentions for Fennec Pharmaceuticals and 7 mentions for Elevation Oncology. Fennec Pharmaceuticals' average media sentiment score of 0.54 beat Elevation Oncology's score of 0.04 indicating that Elevation Oncology is being referred to more favorably in the news media.
Fennec Pharmaceuticals has a net margin of 6.33% compared to Fennec Pharmaceuticals' net margin of 0.00%. Elevation Oncology's return on equity of -39.41% beat Fennec Pharmaceuticals' return on equity.
Summary
Fennec Pharmaceuticals beats Elevation Oncology on 10 of the 16 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
